Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

被引：449

作者：

Crews, K. R. ^{[1
]}

Gaedigk, A. ^{[2
,3
]}

Dunnenberger, H. M. ^{[1
]}

Leeder, J. S. ^{[2
,3
]}

Klein, T. E. ^{[4
]}

Caudle, K. E. ^{[1
]}

Haidar, C. E. ^{[1
]}

Shen, D. D. ^{[5
,6
]}

Callaghan, J. T. ^{[7
,8
]}

Sadhasivam, S. ^{[9
,10
]}

Prows, C. A. ^{[11
,12
]}

Kharasch, E. D. ^{[13
]}

Skaar, T. C. ^{[7
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Therapeut Innovat, Kansas City, MO USA

[3] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[4] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[5] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA

[6] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA

[7] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

[8] RLR VA Med Ctr, Dept Vet Affairs, Indianapolis, IN USA

[9] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA

[10] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA

[11] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA

[12] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Cincinnati, OH 45229 USA

[13] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 04期

基金：

美国医疗保健研究与质量局;

关键词：

CYP2D6 ACTIVITY SCORE; BREAST-FED NEONATE; ULTRARAPID-METABOLISM; MORPHINE FORMATION; CANCER-PATIENTS; OXYCODONE; TRAMADOL; PHARMACOKINETICS; PHENOTYPE; PHARMACODYNAMICS;

D O I：

10.1038/clpt.2013.254

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

引用

页码：376 / 382

页数：7

共 50 条

[31] Crystal structure of human cytochrome P450 2D6
Rowland, P
Blaney, FE
Smyth, MG
Jones, JJ
Leydon, VR
Oxbrow, AK
Lewis, CJ
Tennant, MG
Modi, S
Eggleston, DS
Chenery, RJ
Bridges, AM
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (11) : 7614 - 7622
[32] Cytochrome P450 2D6 polymorphism and character traits
Suzuki, E
Kitao, Y
Ono, Y
Iijima, Y
Inada, T
PSYCHIATRIC GENETICS, 2003, 13 (02) : 111 - 113
[33] Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics
Kirchheiner, J
Heesch, C
Bauer, S
Meisel, C
Seringer, A
Goldammer, M
Tzvetkov, M
Meineke, I
Roots, I
Brockmöller, J
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (04) : 302 - 312
[34] Association study between cytochrome P450 2D6 genotype and patients with methamphetamine dependence
Otani, Kyohei
Ujike, Hiroshi
Sakai, Ayumu
Tanaka, Yuji
Uchida, Naohiko
Nomura, Akira
Morita, Yukitaka
Kishimoto, Makiko
Morio, Akiko
Inada, Toshiya
Harano, Mutsuo
Komiyama, Tokutaro
Hori, Toru
Yamada, Mitsuhiko
Sekine, Yoshimoto
Iwata, Nakao
Iyo, Masaomi
Sora, Ichiro
Ozaki, Norio
Kuroda, Shigetoshi
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (04) : A31 - A32
[35] An investigation of morphine-to-codeine metabolic ratios in postmortem blood, drug interactions, and cytochrome P450 2D6 (CYP2D6) genotype
Lam, Jessica
Woodall, Karen
Solbeck, Patricia
Ross, Colin J. D.
Carleton, Bruce
Hayden, Michael R.
Koren, Gideon
Madadi, Parvaz
FASEB JOURNAL, 2013, 27
[36] The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction
M C Rebsamen
J Desmeules
Y Daali
A Chiappe
A Diemand
C Rey
J Chabert
P Dayer
D Hochstrasser
M F Rossier
The Pharmacogenomics Journal, 2009, 9 : 34 - 41
[37] The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction
Rebsamen, M. C.
Desmeules, J.
Daali, Y.
Chiappe, A.
Diemand, A.
Rey, C.
Chabert, J.
Dayer, P.
Hochstrasser, D.
Rossier, M. F.
PHARMACOGENOMICS JOURNAL, 2009, 9 (01): : 34 - 41
[38] Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
de Leon, Jose
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2015, 54 (07): : 532 - 534
[39] Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificancePart II
Shu-Feng Zhou
Clinical Pharmacokinetics, 2009, 48 : 761 - 804
[40] Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificancePart I
Shu-Feng Zhou
Clinical Pharmacokinetics, 2009, 48 : 689 - 723

← 1 2 3 4 5 →